# A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

> **NCT04539496** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sihuan Pharmaceutical Holdings Group Ltd.** · enrollment: 402 (actual)

## Conditions studied

- Metastasis Solid Tumors
- Advanced Breast Cancer

## Interventions

- **DRUG:** XZP-3287
- **DRUG:** XZP-3287;Letrozole;Anastrozole;Fulvestrant
- **DRUG:** XZP-3287

## Key facts

- **NCT ID:** NCT04539496
- **Lead sponsor:** Sihuan Pharmaceutical Holdings Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-22
- **Primary completion:** 2023-07-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04539496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04539496, "A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04539496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*